At AGBB, leadership means being present when decisions shape the future of health, science, and responsible innovation.
Last week, Dr. Adam Pearlman, MD, MPH, FACP, Chief Medical Advisor to AGBB, was present at the White House during the signing of historic federal legislation impacting marijuana classification under Donald Trump.
AGBB is the parent company of Aspen Green and BOLO, and this moment reflects our responsibility to lead with medical integrity, transparency, and long-term vision across our portfolio of wellness brands.
This milestone represents an important step forward for scientific research, clinical exploration, and informed dialogue around health and regulation in the United States. It also signals tangible momentum beyond policy alone. Last week, the administration indicated that insurance companies will begin covering up to $500 per year for adults over 65 who use high-quality, tested, and approved CBD products, starting in 2026. This annual subsidy is expected to increase as clinical and real-world data continue to demonstrate effectiveness.
In addition to progress across medical, research, and regulatory domains, this development represents a meaningful win for consumers—expanding access, affordability, and evidence-based use of cannabinoid wellness products.
As CEO of AGBB, I believe progress happens when medicine, science, and policy are part of the same conversation. Dr. Pearlman’s presence reflects our commitment to evidence-based leadership, responsible innovation, and building trust at every level of our organization.
Why This Matters to AGBB
AGBB operates with a long-term, science-first mindset. As the parent company behind Aspen Green and BOLO, we believe credibility is earned through informed leadership, responsible product development, and respect for evolving regulatory frameworks.
Our approach is defined by:
- Medical and scientific leadership
- Responsible formulation and transparency
- Long-term consumer trust
- Alignment with regulatory evolution
Being present at pivotal policy moments reinforces our responsibility to build brands informed by expertise—not trends.
Medical Leadership at the Table
Dr. Pearlman’s role at AGBB ensures our brands remain grounded in clinical insight and real-world medical experience. As Chief Medical Advisor, he has also helped formulate Aspen Green’s products, guiding standards for quality, safety, and evidence-based development. His participation in national policy moments reflects the growing importance of informed medical voices in shaping the future of wellness and functional innovation.
CEO Statement
“AGBB is committed to building brands the right way—by prioritizing science, responsibility, and long-term trust. As the parent company of Aspen Green and BOLO, medical leadership at moments like this isn’t symbolic; it’s foundational to how we operate.”
— Brandon Lewis, CEO, AGBB
Compliance & Transparency
AGBB does not engage in political advocacy. Our focus remains on science-led innovation, medical integrity, and responsible growth within evolving regulatory environments.
